Help for osteoarthritis patients
Client
Sanofi-Aventis Deutschland GmbH
Osteoarthritis is often painful and leads to severe movement restrictions. The endpoint of progressive disease is often a required operation with artificial joint replacement.
A promising therapeutic approach is treatment with the high molecular weight hyaluronic acid Synvisc® (Hylan G-F 20). Its efficacy is demonstrated in numerous studies. The result is pain relief, along with an increase in mobility and with it, quality of life.
For the 11 million people affected, one thing is most important in everyday life: mobility. The cross-media campaign will be rolled out in highly visible public formats.
Our work:
Strategic analysis and campaign development
For more information:
synvisc.de
Client
Sanofi-Aventis Deutschland GmbH
Osteoarthritis is often painful and leads to severe movement restrictions. The endpoint of progressive disease is often a required operation with artificial joint replacement.
A promising therapeutic approach is treatment with the high molecular weight hyaluronic acid Synvisc® (Hylan G-F 20). Its efficacy is demonstrated in numerous studies. The result is pain relief, along with an increase in mobility and with it, quality of life.
For the 11 million people affected, one thing is most important in everyday life: mobility. The cross-media campaign will be rolled out in highly visible public formats.
Our work:
Strategic analysis and campaign development
For more information:
synvisc.de
